Vis enkel innførsel

dc.contributor.authorBarkovskaya, Anna
dc.contributor.authorSeip, Kotryna
dc.contributor.authorHilmarsdòttir, Bylgja
dc.contributor.authorMælandsmo, Gunhild Mari
dc.contributor.authorMoestue, Siver Andreas
dc.contributor.authorItkonen, Harri
dc.date.accessioned2019-04-25T07:27:52Z
dc.date.available2019-04-25T07:27:52Z
dc.date.created2019-03-28T09:31:48Z
dc.date.issued2019
dc.identifier.issn2045-2322
dc.identifier.urihttp://hdl.handle.net/11250/2595358
dc.description.abstractPost-translational modification of intracellular proteins with a single N-acetylglucosamine sugar (O-GlcNAcylation) regulates signaling, proliferation, metabolism and protein stability. In breast cancer, expression of the enzyme that catalyzes O-GlcNAcylation – O-GlcNAc-transferase (OGT), and the extent of protein O-GlcNAcylation, are upregulated in tumor tissue, and correlate with cancer progression. Here we compare the significance of O-GlcNAcylation in a panel of breast cancer cells of different phenotypes. We find a greater dependency on OGT among triple-negative breast cancer (TNBC) cell lines, which respond to OGT inhibition by undergoing cell cycle arrest and apoptosis. Searching for the cause of this response, we evaluate the changes in the proteome that occur after OGT inhibition or knock-down, employing a reverse-phase protein array (RPPA). We identify transcriptional repressor - hairy and enhancer of split-1 (HES1) - as a mediator of the OGT inhibition response in the TNBC cells. Inhibition of OGT as well as the loss of HES1 results in potent cytotoxicity and apoptosis. The study raises a possibility of using OGT inhibition to potentiate DNA damage in the TNBC cells.nb_NO
dc.language.isoengnb_NO
dc.publisherNature Researchnb_NO
dc.rightsNavngivelse 4.0 Internasjonal*
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/deed.no*
dc.titleO-GlcNAc Transferase Inhibition Differentially Affects Breast Cancer Subtypesnb_NO
dc.typeJournal articlenb_NO
dc.typePeer reviewednb_NO
dc.description.versionpublishedVersionnb_NO
dc.source.volume9nb_NO
dc.source.journalScientific Reportsnb_NO
dc.source.issue1nb_NO
dc.identifier.doi10.1038/s41598-019-42153-6
dc.identifier.cristin1688438
dc.relation.projectKreftforeningen: 90393200nb_NO
dc.relation.projectNorges forskningsråd: 239940nb_NO
dc.description.localcodeOpen Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.nb_NO
cristin.unitcode194,65,25,0
cristin.unitcode194,65,15,0
cristin.unitnameInstitutt for sirkulasjon og bildediagnostikk
cristin.unitnameInstitutt for klinisk og molekylær medisin
cristin.ispublishedfalse
cristin.fulltextoriginal
cristin.qualitycode1


Tilhørende fil(er)

Thumbnail

Denne innførselen finnes i følgende samling(er)

Vis enkel innførsel

Navngivelse 4.0 Internasjonal
Med mindre annet er angitt, så er denne innførselen lisensiert som Navngivelse 4.0 Internasjonal